Epigenomics AG Enters into R&D Collaboration with Myriad Genetics Inc. to Discover DNA Methylation Biomarkers
Epigenomics AG has entered into an R&D collaboration with Myriad Genetics, Inc. to identify and analyze DNA methylation biomarkers that may predict patients' response to an undisclosed marketed oncology drug.
Under the agreement, Epigenomics will use its proprietary Differential Methylation Hybridization (DMH) microarray platform to perform genome-wide DNA methylation profiling on samples provided by Myriad and compare these profiles to identify DNA methylation biomarkers associated with sensitivity and resistance to the drug.
Epigenomics will also apply its OncoSign(TM) approach that is offered in collaboration with its partner CellTrend GmbH for fast track identification of DNA methylation biomarkers for the drug in an established panel of human tumor cell lines. Financial details were not disclosed.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Association for Professionals in Infection Control and Epidemiology, Inc. (APIC) - Washington, USA
Hereditary_nonpolyposis_colorectal_cancer
ClinTec’s CEO, Dr Rabinder Buttar wins the Institute of Directors, Director of the Year Award for Glasgow & West of Scotland
Rescue protein gives doomed cells a stay of 'execution'
Weill Cornell, Ithaca researchers use cotton candy to create new bloodflow routes
Discovery of a gene that causes chronic lymphocytic leukemia - CSIC researchers lead a study that shows that more than 82% of patients with this pathology have high levels of the RRAS2 gene.
Reverie Labs - Boston, USA
New model finds HIV acute phase infectivity may be lower than previously estimated
New findings on the evolution of bacterial antibiotic resistance - Plasmids and bacterial cells do not always play in the same team
Scientists find key to regenerating blood vessels
